Letter to the editor on Body mass index and 20-specific cancers-re-analyses of dose-response meta-analyses of observational studies by Markozannes, G. et al.
Letter to the editor on ‘Body mass index
and 20-specific cancers—re-analyses of
dose-response meta-analyses of observa-
tional studies’
In a recently published paper in the Annals of Oncology [1], Choi
et al. evaluated the strength of the evidence in the literature for the
association between body mass index and 20 cancers in a manner
that resembles our umbrella review on the same topic [2]. We were
surprised to see that there were many discrepancies between the
two assessments. The current paper used a grading scheme consist-
ing of similar criteria used in our umbrella review, but structured
the grading differently without providing a justification for this
choice. Our umbrella review used a grading scheme that has been
extensively applied and justified in previous studies [3], and the
results for adiposity and cancer in our study were consistent with
previous assessments by the World Cancer Research Fund
(WCRF) and the International Agency for Research on Cancer
(IARC) (Table 1) [4, 5]. We feel that the authors’ choice of grading
scheme fails to correctly classify the evidence. Associations between
adiposity and risk of postmenopausal breast, colon, gallbladder,
gastric, liver, ovarian and thyroid cancers received weak or not sig-
nificant evidence grades in the current paper in contrast to con-
vincing evidence grades received in the previous reports [2, 4, 5].
There are also a number of other methodological concerns that
may affect the validity of the evidence grading in the current pa-
per. First, the authors pooled studies from several meta-analyses
on the same topic (e.g. for prostate and pancreatic cancer) with-
out acknowledging/correcting for study overlap across meta-
analyses, which is substantial. Second, the authors updated exist-
ing meta-analyses by selectively adding only one newly published
study without conducting a systematic literature search. Third,
the authors do not report or differentiate their analysis by study
design (e.g. cohort versus case–control), which may have impor-
tant implications in the quality of the evidence. Fourth, several
associations by cancer subsite or according to modifying factors
have been omitted from the current paper (e.g. by menopausal
status or hormone replacement therapy use for gynaecological
malignancies). Fifth, the authors used a P-value threshold of 0.05
for Egger’s regression asymmetry test as evidence for small-study
effects, but this test is known to be underpowered and 0.10 is the
widely accepted threshold.
In summary, IARC, WCRF and our umbrella review have rated
the quality of evidence in the field of adiposity and cancer by us-
ing different methodologies, but reached similar conclusions. In
contrast, we are afraid that the current paper fails to correctly
classify this evidence.
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Table 1. Strength of the evidence for the association of adiposity and cancer as evaluated by different organizations/investigators
Type Choi et al. IARC WCRF 2017 Kyrgiou et al.
Breast cancer, premenopausal Weak NA Probable decreased risk Suggestive
Breast cancer, postmenopausal Weak Sufficient Convincing increased risk Strong (never HRT use)
Colon cancer Weak Sufficient Convincing increased riska Strong (men)
Rectal cancer Convincing Sufficient Convincing increased riska Strong (men)
Endometrial cancer Convincing Sufficient Convincing increased risk Strong
Gallbladder cancer Weak Sufficient Probable increased risk Strong
Gastric cancer Non-significant Sufficient Probable increased risk (cardia only) Strong (cardia)
Leukemia Convincing NR NR Highly suggestive
Liver cancer Weak Sufficient Convincing increased risk Highly suggestive
Lung cancer Weak Inadequate Limited-no conclusion Suggestive (smokers)
Melanoma NR Inadequate NR Weak
Multiple myeloma Convincing Sufficient NR Strong
Non-Hodgkin’s lymphoma Suggestive Limited NR Suggestive
Esophageal adenocarcinoma Convincing (men) Sufficient Convincing increased risk Strong
Ovarian cancer Weak Sufficient Probable increased risk Strong
Pancreatic cancer Convincing Sufficient Convincing increased risk Strong
Prostate cancer Non-significant Limited Probable increased risk (advanced) Highly suggestive (mortality)
Renal cell carcinoma Convincing Sufficient Convincing increased risk Strong
Thyroid cancer Weak Sufficient NR Suggestive
aEvaluated as colorectal.
NR, not reported; HRT, hormone replacement therapy; WCRF, World Cancer Research Fund; IARC, International Agency for Research on Cancer.
Letters to the editor Annals of Oncology
1490 | Letters to the editor Volume 29 | Issue 6 | 2018
Downloaded from https://academic.oup.com/annonc/article-abstract/29/6/1490/4979449
by University of Helsinki user
on 03 August 2018
Funding
This work was supported by Genesis Research Trust (Garfeld
Weston Foundation, P63522 to MK); Sigrid Jusélius Fellowship
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